Perimeter Medical Imaging AI Enters Systemwide Agreement with Intermountain Health
Intermountain Health has signed a systemwide agreement enabling its hospitals to deploy Perimeter Medical Imaging AI's S-Series OCT for real-time tissue visualization in the OR. Initial sites include Intermountain Health LDS Hospital in Salt Lake City and Intermountain Health American Fork Hospital in American Fork, Utah, with access available across the broader network in the Mountain West.
Why this matters to clinicians and OR teams
- Intraoperative insight: S-Series OCT provides real-time, cross-sectional views of excised tissue microstructure that can support on-the-spot surgical decisions.
- Scalable access: Any Intermountain Health hospital can acquire the technology under this agreement, extending availability to both urban tertiary centers and rural hospitals.
- Data-driven progress: The collaboration includes structured evaluation and data collection to inform ongoing AI algorithm development.
"Perimeter's OCT technology is a valuable tool in my practice because it helps me visualize margins in real-time. This supports more informed surgical decisions," said Dr. Jennifer Tittensor, a breast surgeon at American Fork Hospital. "I'm thrilled that Intermountain Health and Perimeter have partnered to bring this technology to these hospitals."
"This collaboration opens the door for Perimeter to extend our technology into states where it has not yet been deployed, while supporting surgeons with advanced imaging tools that aim to enhance surgical decision-making and improve outcomes for the patients they serve," added Perimeter CEO Adrian Mendes.
Where it launches first
The agreement begins with deployments at LDS Hospital and American Fork Hospital. From there, Intermountain Health's 34 hospitals and approximately 400 clinics across Utah, Idaho, Nevada, Colorado, Montana, and Wyoming can bring the technology online as needed.
About the technology
The FDA-cleared Perimeter S-Series OCT provides real-time, two-dimensional, cross-sectional visualization of excised human tissue at the cellular level, along with software for image review and annotation. It has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for breast tissue, breast cancer, other cancer types, margin evaluation, or reducing re-excision rates. The safety and effectiveness of those uses have not been established.
Perimeter's next-generation, breakthrough-device-designated investigational B-Series OCT with ImgAssist AI was recently evaluated in a pivotal clinical trial, supported by a grant of up to US$7.4 million from the Cancer Prevention and Research Institute of Texas.
Built on prior collaboration
This systemwide agreement builds on a previously announced Development Support Agreement between the organizations. That framework supports evaluation of clinical value and collection of additional data to refine Perimeter's AI capabilities.
About Intermountain Health
Headquartered in Utah, Intermountain Health operates 34 hospitals, approximately 400 clinics, medical groups with about 4,600 employed physicians and advanced care providers, and a health plan division (Select Health) with more than one million members. The system focuses on evidence-based care and sustainable outcomes across a wide geographic footprint in the western U.S.
About Perimeter Medical Imaging AI, Inc.
Based in Toronto and Dallas, Perimeter Medical Imaging AI (TSXV: PINK) (OTCQX: PYNKF) develops ultra-high-resolution, real-time imaging tools to address needs in cancer surgery. The company's ticker "PINK" references the pink ribbon widely recognized during Breast Cancer Awareness Month.
Regulatory and use notes
- Intended use: S-Series OCT is indicated for imaging and evaluation of excised human tissue microstructure, providing two-dimensional, real-time depth visualization with image review and annotation tools.
- Unapproved uses: S-Series OCT has not been evaluated by the U.S. FDA specifically for breast tissue, breast cancer, other cancer types, margin evaluation, or reducing re-excision rates. Safety and effectiveness for these uses have not been established.
Forward-looking note
This update includes forward-looking statements and information that involve risks and uncertainties. Actual results may differ materially due to factors such as clinical adoption, regulatory outcomes, operational constraints, and market conditions. Words such as "may," "could," "will," "expect," "anticipate," and similar terms are intended to identify such statements; readers should not place undue reliance on them.
Further resources
- FDA: 510(k) clearance overview
- Training: AI courses by job role for healthcare leaders planning workforce upskilling
Your membership also unlocks:
